Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328118 | 0.95 | KCNK3 (0.41) | HTR6BCHEFNTAFNTBKCNK3 | |
| SCHEMBL17317606 | 0.92 | KCNK3 (0.41) | HTR6BCHEFNTAFNTBKCNK3 | |
| SCHEMBL19110751 | 0.91 | HTR6 (0.44) | HTR6BCHEFNTAFNTBKCNK3 | |
| SCHEMBL17317871 | 0.91 | KCNK3 (0.44) | FNTAFNTBKCNK3ENPP2PREP | |
| SCHEMBL17328130 | 0.90 | KCNK3 (0.49) | FNTAFNTBKCNK3ENPP2DPP4 | |
| SCHEMBL17317547 | 0.89 | ENPP2 (0.42) | KCNK3ENPP2DPP4DPP8DPP9 | |
| SCHEMBL17317584 | 0.88 | KCNK3 (0.44) | FNTAFNTBKCNK3ENPP2DPP4 | |
| SCHEMBL17317679 | 0.86 | KCNK3 (0.49) | KCNK3PREPDPP4DPP8DPP9 | |
| Formic Acid SCHEMBL17317592 | 0.86 | KCNK3 (0.42) | FNTAFNTBKCNK3ENPP2DPP4 | |
| SCHEMBL19110783 | 0.86 | PREP (0.42) | HTR6BCHEFNTAFNTBKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | HTR6 454/4885BCHE 1328/4885FNTA 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.